Emerging Growth Stocks Experience Significant Gains in After-Hours Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Should l Buy BFLY?
Source: NASDAQ.COM
Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.
Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.
Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.
Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.730
Low
4.00
Averages
4.25
High
4.50
Current: 3.730
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Benzinga Stock Whisper Index Analysis for the Week Ending March 6
- Investor Focus: Benzinga's Stock Whisper Index utilizes proprietary data and pattern recognition each week to highlight five undervalued and under-followed stocks, aiding investors in uncovering potential opportunities.
- Information Overload Challenge: Retail traders face the challenge of sifting through an abundance of methods to identify stocks worth attention, underscoring the complexity of market information.
- Market Dynamics Tracking: Benzinga Pro offers the latest market dynamics and headlines, ensuring investors can stay updated on significant events and trends that impact the market, enhancing decision-making efficiency.
- Future Report Preview: Benzinga encourages investors to look forward to next week's report, continuously tracking market movements to seize potential investment opportunities.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
TD Cowen Raises Butterfly Network Price Target to $6
- Price Target Increase: TD Cowen raised Butterfly Network's price target from $4.50 to $6 while maintaining a Buy rating, reflecting market confidence in the company's future growth potential.
- Strong Earnings Report: Butterfly Network reported an adjusted EPS of 2 cents for Q4, falling short of the consensus estimate of 6 cents, indicating a need for improvement in profitability.
- New Revenue Stream: The company anticipates that Butterfly Embedded will become a significant part of future growth, as it supplements its core POCUS business, potentially driving stock price appreciation and marking a shift towards a more tech-oriented focus.
- Optimistic Future Outlook: Butterfly Network projects FY26 revenue between $117 million and $121 million, exceeding the consensus of $110.62 million, showcasing the company's competitive edge and growth potential in the market.
See More
Butterfly Network Reports Record Q4 2025 Revenue and Strategic Growth
- Significant Revenue Growth: Butterfly Network reported fourth-quarter revenue of $31.5 million, a 41% year-over-year increase, achieving positive operating cash flow for the first time, primarily driven by upfront payments from the Midjourney partnership, demonstrating successful execution of its strategic growth plan.
- Product Launch Impact: The launch of Compass AI has provided a substantial tailwind for the enterprise strategy, with over 50% growth in the enterprise pipeline since its release, indicating meaningful progress in the company's transformation into a semiconductor-based ultrasound platform.
- Optimistic Future Outlook: The company projects first-quarter 2026 revenue between $24 million and $28 million, with full-year revenue expected to range from $117 million to $121 million, reflecting a growth rate of approximately 20% to 24%, showcasing management's confidence in future growth.
- Diversified Market Opportunities: Management noted that the HomeCare business is expected to enter its commercial phase in 2026, potentially generating $40 million to $50 million in revenue, further enhancing the company's competitive position and diversifying its revenue streams.
See More
U.S. Stocks Decline Midway, S&P 500 Falls Over 1%
- Market Performance: U.S. stocks traded lower midway through the session, with the S&P 500 falling over 1%, indicating a weakening market trend that could impact investor confidence.
- Company Earnings: Hormel Foods Corp (NYSE:HRL) reported mixed Q1 FY26 results, with adjusted EPS of 34 cents beating the 32 cents consensus, but sales of $3.03 billion missed the $3.07 billion estimate, reflecting sales challenges faced by the company.
- Sector Performance: Energy shares gained 1%, while information technology stocks fell by 2.6%, indicating varied market reactions across sectors that may influence investor asset allocation strategies.
- Economic Data: U.S. natural gas stocks fell by 52 billion cubic feet, exceeding market expectations of a 36 bcf draw, while initial jobless claims rose by 4,000 to 212,000, suggesting potential pressures in the labor market.
See More
Benzinga Stock Whisper Index Analysis for the Week Ending March 6
- Investor Focus: Benzinga's Stock Whisper Index utilizes proprietary data and pattern recognition each week to highlight five undervalued and under-followed stocks, aiding investors in uncovering potential opportunities.
- Information Overload Challenge: Retail traders face the challenge of sifting through an abundance of methods to identify stocks worth attention, underscoring the complexity of market information.
- Market Dynamics Tracking: Benzinga Pro offers the latest market dynamics and headlines, ensuring investors can stay updated on significant events and trends that impact the market, enhancing decision-making efficiency.
- Future Report Preview: Benzinga encourages investors to look forward to next week's report, continuously tracking market movements to seize potential investment opportunities.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
TD Cowen Raises Butterfly Network Price Target to $6
- Price Target Increase: TD Cowen raised Butterfly Network's price target from $4.50 to $6 while maintaining a Buy rating, reflecting market confidence in the company's future growth potential.
- Strong Earnings Report: Butterfly Network reported an adjusted EPS of 2 cents for Q4, falling short of the consensus estimate of 6 cents, indicating a need for improvement in profitability.
- New Revenue Stream: The company anticipates that Butterfly Embedded will become a significant part of future growth, as it supplements its core POCUS business, potentially driving stock price appreciation and marking a shift towards a more tech-oriented focus.
- Optimistic Future Outlook: Butterfly Network projects FY26 revenue between $117 million and $121 million, exceeding the consensus of $110.62 million, showcasing the company's competitive edge and growth potential in the market.
See More
Butterfly Network Reports Record Q4 2025 Revenue and Strategic Growth
- Significant Revenue Growth: Butterfly Network reported fourth-quarter revenue of $31.5 million, a 41% year-over-year increase, achieving positive operating cash flow for the first time, primarily driven by upfront payments from the Midjourney partnership, demonstrating successful execution of its strategic growth plan.
- Product Launch Impact: The launch of Compass AI has provided a substantial tailwind for the enterprise strategy, with over 50% growth in the enterprise pipeline since its release, indicating meaningful progress in the company's transformation into a semiconductor-based ultrasound platform.
- Optimistic Future Outlook: The company projects first-quarter 2026 revenue between $24 million and $28 million, with full-year revenue expected to range from $117 million to $121 million, reflecting a growth rate of approximately 20% to 24%, showcasing management's confidence in future growth.
- Diversified Market Opportunities: Management noted that the HomeCare business is expected to enter its commercial phase in 2026, potentially generating $40 million to $50 million in revenue, further enhancing the company's competitive position and diversifying its revenue streams.
See More
U.S. Stocks Decline Midway, S&P 500 Falls Over 1%
- Market Performance: U.S. stocks traded lower midway through the session, with the S&P 500 falling over 1%, indicating a weakening market trend that could impact investor confidence.
- Company Earnings: Hormel Foods Corp (NYSE:HRL) reported mixed Q1 FY26 results, with adjusted EPS of 34 cents beating the 32 cents consensus, but sales of $3.03 billion missed the $3.07 billion estimate, reflecting sales challenges faced by the company.
- Sector Performance: Energy shares gained 1%, while information technology stocks fell by 2.6%, indicating varied market reactions across sectors that may influence investor asset allocation strategies.
- Economic Data: U.S. natural gas stocks fell by 52 billion cubic feet, exceeding market expectations of a 36 bcf draw, while initial jobless claims rose by 4,000 to 212,000, suggesting potential pressures in the labor market.
See More
